Cefotiam

Cefotiam Overview

Cefotiam (chemical formula C18H23N9O4S3) is a semi-synthetic, broad-spectrum second-generation beta-lactam antibiotic belonging to the cephalosporin class. Chemically, it belongs to the class of organic compounds known as cephalosporins within the lactams superclass. Structurally, it consists of a fused 7-aminocephalosporanic acid (7-ACA) core comprising a beta-lactam ring fused to a dihydrothiazine ring substituted at the 7-position with a 2-(2-aminothiazol-4-yl)acetamido group and at the 3-position with a 1-(2-dimethylaminoethyl)-1H-tetrazol-5-ylthiomethyl side chain.

In clinical infectious disease and acute hospital care, Cefotiam functions as a broad-spectrum, parenteral bactericidal antimicrobial agent (ATC code J01DC07). Formulated as Cefotiam hydrochloride for intravenous or intramuscular injection, and as an oral prodrug ester (Cefotiam hexetil; historically marketed under brand names such as Pansporin and Ceradon by Takeda Pharmaceutical), it is indicated for the treatment of severe, susceptible bacterial infections. These include lower respiratory tract infections (pneumonia, lung abscess), complicated urinary tract infections, intra-abdominal and biliary tract infections, skin and soft tissue infections, osteomyelitis, and bacteremia. Widely utilized across Japan, Asia, and Europe, Cefotiam is distinguished by its high stability against classic penicillinases and extended Gram-negative coverage compared to first-generation cephalosporins.

What Is Cefotiam and How Does It Work?

Cefotiam acts primarily through inhibition of bacterial peptidoglycan cell wall synthesis.

Its primary chemical, physiological, and cellular mechanisms include:

• Penicillin-Binding Protein (PBP) Inhibition: Cefotiam diffuses across bacterial outer cell wall porin channels and binds with high affinity to essential penicillin-binding proteins (PBPs) including PBP 1A, PBP 1B, PBP 2, and PBP 3 (peptidoglycan D,D-transpeptidase FtsI) in Gram-positive and Gram-negative eubacteria.
• Inhibition of Transpeptidation Cross-Linking: By acylating the active-site serine residue of PBPs, Cefotiam blocks the final transpeptidation step of peptidoglycan synthesis, halting the structural cross-linking of the bacterial cell wall lattice during active cell division.
• Autolysin Activation & Bactericidal Lysis: Halting cell wall assembly combined with uninhibited activity of endogenous bacterial autolysins and murein hydrolases leads to cell elongation, spheroplast formation, osmotic instability, and rapid autolytic cell death.
• Aminothiazole Ring Advantage: The 2-aminothiazolyl side chain at the 7-position enhances affinity for PBPs of Gram-negative bacilli and increases resistance to hydrolysis by classic TEM-1 and SHV-1 plasmid-mediated beta-lactamases.

Is Cefotiam FDA Approved?

No, Cefotiam is not approved or commercially marketed in the United States by the US FDA. However, it is an established, approved prescription antibiotic in Japan, South Korea, China, and several European nations. Cefuroxime, cefaclor, and cefotetan serve as standard US FDA-approved second-generation cephalosporin equivalents.

What Is Cefotiam Used For?

• Treatment of lower respiratory tract infections, including community-acquired and nosocomial pneumonia, bronchiectasis, and lung abscess caused by susceptible S. pneumoniae, H. influenzae, or K. pneumoniae.
• Treatment of complicated and uncomplicated urinary tract infections (pyelonephritis, cystitis) caused by E. coli, P. mirabilis, or Klebsiella species.
• Treatment of intra-abdominal and biliary tract infections (cholecystitis, cholangitis, peritonitis).
• Treatment of skin, soft tissue, and wound infections (cellulitis, abscesses, surgical site infections) caused by susceptible staphylococci or streptococci.
• Treatment of bone and joint infections (acute osteomyelitis, septic arthritis) and bacteremia/septicemia.

Before Receiving Cefotiam: Contraindications & Precautions

Screen for severe immediate-type hypersensitivity to cephalosporins, penicillins, or other beta-lactam antibiotics. Use in pregnancy only under explicit medical supervision, as human safety trials are limited despite low animal teratogenicity. Monitor nursing infants for diarrhea or thrush, and adjust dosing in renal impairment to avoid neurotoxicity.

Who Should Not Receive Cefotiam?

• Individuals with a documented severe hypersensitivity (anaphylaxis, severe urticaria, laryngeal edema) to Cefotiam, other cephalosporins, or beta-lactam antibiotics.
• Patients with a history of severe immediate-type hypersensitivity reactions to penicillins or carbapenems.

Cefotiam, Pregnancy & Lactation

Cephalosporins cross the placental barrier. Reproductive toxicology studies in animals demonstrate no evidence of teratogenicity or direct fetal harm (Pregnancy Category B equivalent). Cefotiam should be used during pregnancy only if clearly needed under medical supervision. Cefotiam is excreted in low concentrations in human breast milk; exercise caution and monitor nursing infants for changes in bowel flora (diarrhea) or oral candidiasis (thrush).

Tell Your Doctor Before Receiving Cefotiam

Inform your physician if you have a history of severe asthma, kidney disease, gastrointestinal disease (especially colitis), or a history of severe drug allergies.

Cefotiam Dosage & Administration

Standard adult parenteral dosing (IV or IM) is 1 g to 2 g daily in 2 to 4 divided doses, up to 4 g daily for severe infections. Pediatric parenteral dosing is 40 mg/kg to 80 mg/kg daily in 3 to 4 divided doses, escalated to 100 mg/kg daily for severe cases. Oral Cefotiam hexetil prodrug is dosed at 200 mg to 400 mg 2 to 3 times daily after meals.

Standard Dosing Guidelines

• Adult Parenteral Dosing (IV or IM): Standard adult dosage is 1 g to 2 g daily, administered intravenously or intramuscularly in 2 to 4 divided doses (e.g., 500 mg to 1 g every 8 to 12 hours). In severe or life-threatening infections (such as sepsis or refractory pneumonia), dosing may be increased up to 4 g daily in divided doses.
• Adult Oral Dosing (Cefotiam Hexetil Prodrug, where available): 200 mg to 400 mg taken orally 2 to 3 times daily after meals.
• Pediatric Parenteral Dosing: 40 mg/kg to 80 mg/kg of body weight daily, divided into 3 to 4 equal doses (every 6 to 8 hours). In severe pediatric infections, dosage may be escalated up to 100 mg/kg/day.

How Cefotiam Is Administered

• Intravenous Infusion: Reconstitute Cefotiam hydrochloride sterile powder with Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose. Administer via direct slow IV injection over 3 to 5 minutes or dilute further for intermittent IV infusion over 30 to 60 minutes.
• Intramuscular Injection: Reconstitute with sterile water or 0.5% lidocaine hydrochloride solution to reduce local injection pain. Inject deeply into a large muscle mass (such as the gluteal muscle).

Cefotiam Clinical Efficacy & Research

Clinical infectious disease trials in Asia and Europe establish that parenteral Cefotiam achieves high clinical and microbiological cure rates (85% to 92%) in acute bacterial respiratory, urinary, and biliary tract infections. Pharmacokinetic studies demonstrate that Cefotiam achieves high drug concentrations in lung tissue, sputum, bile, gallbladder tissue, and renal parenchyma, far exceeding the minimum inhibitory concentrations (MICs) of common uropathogens and respiratory pathogens.

Cefotiam Side Effects & Safety Profile

Binds penicillin-binding proteins (PBPs) to halt peptidoglycan cell wall cross-linking, inducing autolysins and osmotic cell death. Common side effects include mild diarrhea, nausea, skin rash, and injection site pain or phlebitis. Serious risks include anaphylaxis, Clostridioides difficile-associated diarrhea (CDAD), severe cutaneous reactions, and CNS neurotoxicity (seizures, encephalopathy) in unadjusted renal impairment.

Common Side Effects

• Localized reactions: Injection site pain, induration, and vein irritation/phlebitis following IV infusion.
• Gastrointestinal: Mild diarrhea, loose stools, nausea, vomiting, and loss of appetite.
• Dermatological: Mild allergic skin rash, urticaria, pruritus, and drug fever.

Serious Adverse Events

• Severe Anaphylaxis & Hypersensitivity: Bronchospasm, facial angioedema, urticaria, and cardiovascular collapse.
• Clostridioides difficile-Associated Diarrhea (CDAD): Pseudomembranous colitis ranging from mild watery diarrhea to severe toxic megacolon.
• Severe Cutaneous Adverse Reactions (SCARs): Rare instances of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme.
• Hematologic Dyscrasias: Reversible neutropenia, leukopenia, thrombocytopenia, and positive direct Coombs’ test.

Managing Side Effects

If severe allergic reactions or anaphylaxis occur, stop the drug immediately and administer epinephrine, airway support, and IV fluids. Discontinue if severe watery diarrhea develops and evaluate for C. difficile toxins.

Cefotiam Drug Interactions & What to Avoid

Co-administration with probenecid inhibits OAT1/3 tubular secretion, markedly elevating Cefotiam serum levels and half-life. Concomitant use with aminoglycosides or loop diuretics increases nephrotoxicity risks, while oral anticoagulants require close INR monitoring due to disrupted gut flora. Avoid alcohol during oral prodrug therapy to minimize GI distress.

Drug-Drug Interactions

• Organic Anion Transporter Inhibitors (e.g., Probenecid): Probenecid inhibits OAT1 (SLC22A6) and OAT3 (SLC22A8) renal tubular secretion of Cefotiam, significantly elevating peak serum concentrations and extending its elimination half-life.
• Nephrotoxic Drugs (e.g., Aminoglycosides, Polymyxins, Loop Diuretics): Concurrent use with aminoglycosides or furosemide may increase the risk of enhanced nephrotoxicity; monitor renal function parameters.
• Oral Anticoagulants (e.g., Warfarin): May alter prothrombin time (INR) by suppressing vitamin K-producing intestinal flora; monitor INR closely.

Food & Alcohol

Parenteral administration is managed in clinical settings. For oral Cefotiam hexetil prodrug formulations, taking doses after meals significantly increases gastrointestinal prodrug absorption and systemic bioavailability. Avoid alcohol to minimize gastrointestinal distress and liver strain.

Cefotiam Overdose, Emergency & Clearance

Cleared primarily unchanged by the kidneys via glomerular filtration and tubular secretion with an elimination half-life of 0.8 to 1.1 hours (6 to 10 hours in severe renal failure). Overdose triggers central nervous system hyperexcitability, muscle twitching, and seizures managed with supportive care and hemodialysis. Store sterile powder at 15°C to 25°C protected from light; reconstituted IV solutions remain stable for 12 to 24 hours at room temperature and 72 hours under refrigeration.

Elimination Kinetics & Overdose

Cefotiam is poorly absorbed orally as a free acid, requiring parenteral administration or esterification to Cefotiam hexetil. It binds weakly-to-moderately to plasma proteins (approx. 40%) and distributes into lung, biliary, peritoneal, and urinary tract tissues. CSF penetration across uninflamed meninges is low, but increases slightly with active meningeal inflammation. It undergoes zero hepatic biotransformation and is excreted unchanged by the kidneys via glomerular filtration and active tubular secretion (approx. 60% to 75% recovered in urine within 6 hours).

Storage & Handling

Store sterile powder vials at controlled room temperature between 15°C and 25°C (59°F to 77°F), protected from direct light and excessive heat. Reconstituted intravenous solutions maintain stability for 12 to 24 hours at room temperature or up to 72 hours under refrigeration (2°C to 8°C). Keep strictly out of reach of children.

Cefotiam Patient Management & Safety Protocols

Confirm no prior severe beta-lactam allergy and evaluate renal function (serum creatinine / eGFR) before initiating therapy. Monitor IV sites daily for phlebitis, track infection resolution (fever, WBC count), and instruct patients to report severe watery diarrhea or reduced urine output immediately.

Clinical Monitoring Checklist

• Verify no prior history of severe penicillin or cephalosporin allergy before initiating therapy.
• Monitor resolution of infection symptoms (fever, WBC count, resolution of purulent sputum/urine).
• Perform baseline and periodic renal function assays (serum creatinine, BUN) in patients with kidney disease.
• Assess IV site daily for signs of phlebitis or extravasation.
• Adjust dosing based on creatinine clearance in renal impairment.

Key Do’s and Don’ts

• Do report severe watery diarrhea, unusual skin rash, or reduced urine output immediately.
• Do adjust dosage in patients with moderate-to-severe renal impairment.
• Do monitor kidney function when co-administered with nephrotoxic drugs.
• Do not administer if the patient has a history of severe anaphylactic reaction to beta-lactam antibiotics.
• Do not give via rapid unmonitored IV push.

Frequently Asked Questions

References

• DrugBank Database – Cefotiam Profile (DB00229)
• Classyfire Database – Cephalosporins Chemical Taxonomy Profile
• Japanese Pharmacopoeia (JP XVII) – Cefotiam Hydrochloride Monograph

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a         licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.